Prospective Multicenter International Surveillance of Azole Resistance in Aspergillus fumigatus
J.W.M. van der Linden
, M.C. Arendrup, A. Warris, K. Lagrou, H. Pelloux, P.M. Hauser, E. Chryssanthou, E. Mellado, S.E. Kidd, A.M. Tortorano, E. Dannaoui, P. Gaustad, J.W. Baddley, A. Uekötter, C. Lass-Flörl, N. Klimko, C.B. Moore, D.W. Denning, A.C. Pasqualotto, C. Kibbler, S. Arikan-Akdagli, D. Andes, J. Meletiadis, L. Naumiuk, M. Nucci, W.J.G. Melchers, and P.E. Verweij
Author affiliations: Author affiliations: Radboud University Medical Centre Nijmegen, Nijmegen, the Netherlands (J.W.M. van der Linden, W.J.G. Melchers, P.E. Verweij); Statens Serum Institute, Copenhagen, Denmark (M.C. Arendrup); University of Aberdeen, Aberdeen, UK (A. Warris); Catholic University Leuven, Leuven, Belgium (K. Lagrou); Centre Hospitalier Universitaire, Grenoble, France (H. Pelloux); Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland (P.M. Hauser); Karolinska University Hospital Solna, Stockholm, Sweden (E. Chryssanthou); Instituto de Salud Carlos III, Madrid, Spain (E. Mellado); The Alfred Hospital, Melbourne, Victoria, Australia (S.E. Kidd); Università degli Studi di Milano, Milan, Italy (A.M. Tortorano); Hopital Européen G. Pompidou and Université Paris 5, Paris, France (E. Dannaoui); Oslo University Hospital and Rikshospitalet, Oslo, Norway (P. Gaustad); University of Alabama at Birmingham, Birmingham, Alabama, USA (J.W. Baddley); University of Münster, Münster, Germany (A. Uekötter); University of Innsbruck, Innsbruck, Austria (C. Lass-Flörl); North Western State Medical University, Saint Petersburg, Russia (N. Klimko); University of Manchester and Mycology Reference Centre of the University Hospital of South Manchester, Manchester, UK (C.B. Moore, D.W. Denning); Santa Casa de Misericordia de Porto Alegre and Universidade Federal de Ciencias da Saude de Porto Alegre, Porto Alegre, Brazil (A.C. Pasqualotto); Royal Free London NHS Foundation Trust and University College London, London, UK (C. Kibbler); Hacettepe University Medical School, Ankara, Turkey (S. Arikan-Akdagli); University of Wisconsin, Madison, Wisconsin, USA (D. Andes); Attikon University Hospital, Athens, Greece (J. Meletiadis); Hospital of the Medical University of Gdansk, Gdansk, Poland (L. Naumiuk); Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil (M. Nucci)
Main Article
Figure 2
Figure 2. Patient characteristics and underlying resistance mechanisms of patients with invasive and noninvasive Aspergillus disease. *Otomycosis, dermatomycosis, or onychomycosis; 1 patient had a resistant isolate and otomycosis (patient 9 in the online Technical Appendix Table, http://wwwnc.cdc.gov/EID/article/21/6/14-0717-Techapp1.pdf). †One patient had chronic pulmonary aspergillosis and ABPA. ‡Not classified according to European Organization for the Research and Treatment of Cancer/Mycoses Study Group criteria (5). §One patient is included with 46-bp tandem-repeat resistance mechanism. ABPA, allergic bronchopulmonary aspergillosis; CPA, chronic pulmonary aspergillosis; R, resistant; S, susceptible; –, negative; +, positive.
Main Article
References
Snelders E,
van der Lee HAL,
Kuijpers J,
Rijs AJ,
Varga J,
Samson RA,
Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med.
2008;
5:
e219.
DOIPubMedGoogle Scholar van der Linden JW,
Warris A,
Verweij PE.
Aspergillus species intrinsically resistant to antifungal agents. Med Mycol.
2011;
49:
S82–
9.
DOIPubMedGoogle Scholar van der Linden JW,
Snelders E,
Kampinga GA,
Rijnders BJ,
Mattsson E,
Debets-Ossenkopp YJ,
Clinical implications of azole resistance in Aspergillus fumigatus, the Netherlands, 2007–2009. Emerg Infect Dis.
2011;
17:
1846–
54.
DOIPubMedGoogle Scholar van der Linden JWM, Arendrup MC, van der Lee HAL, Melchers WJG, Verweij PE. Azole containing agar plates as a screening tool for azole resistance of Aspergillus fumigatus. Mycoses. 2009;52: S1–19.9.
De Pauw B,
Walsh TJ,
Donnelly JP,
Stevens DA,
Edwards JE,
Calandra T,
Revised definitions of invasive fungal disease from the EORTC/MSG. Clin Infect Dis.
2008;
46:
1813–
21.
DOIPubMedGoogle Scholar Lass-Florl C,
Cuenca-Estrella M,
Denning D,
Rodriguez-Tudela J.
Antifungal susceptibility testing in Aspergillus spp. according to EUCAST methodology. Med Mycol.
2006;
44:
319–
25.
DOIGoogle Scholar van der Linden JW,
Camps SMT,
Kampinga GA,
Arends JP,
Debets-Ossenkopp YJ,
Haas PJ,
Aspergillosis due to voriconazole highly-resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin Infect Dis.
2013;
57:
513–
20.
DOIPubMedGoogle Scholar
Main Article
Page created: May 15, 2015
Page updated: May 15, 2015
Page reviewed: May 15, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.